Anti-Siglec-15 antibody

Patent metadata

Field	Value
Publication number	US-9751944-B2
Application number	US-201514731519-A
Country	US
Kind code	B2
Filing date	Jun 5, 2015
Priority date	Apr 9, 2009
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising an antibody or antigen binding fragment thereof in an amount effective to inhibit osteoclast differentiation, wherein the antibody or antigen binding fragment comprises: a light chain sequence that comprises a light chain variable region having CDRL1, CDRL2, and CDRL3, wherein CDRL1, comprises the amino acid sequence of SEQ ID NO: 47, CDRL2, comprises the amino acid sequence of SEQ ID NO: 48, and CDRL3, comprises the amino acid sequence of SEQ ID NO: 49, and a heavy chain sequence that comprises a heavy chain variable region having CDRH1, CDRH2, and CDRH3, wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 44, CDRH2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 97, and CDRH3 comprises the amino acid sequence of SEQ ID NO: 46, wherein the antibody or antigen binding fragment thereof binds a Siglec-15 protein comprising the amino acid sequence of SEQ ID NO: 2 or 4, and a pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1 , wherein the antigen binding fragment is an scFv.

3. The pharmaceutical composition of claim 1 , wherein the antibody is a chimeric antibody.

4. The pharmaceutical composition of claim 1 , wherein the antibody or antigen binding fragment is humanized.

5. The pharmaceutical composition of claim 1 , wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 45.

6. The pharmaceutical composition of claim 1 , wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 97.

7. The pharmaceutical composition of claim 1 , wherein the excipient comprises a liquid or a solid.

8. The pharmaceutical composition of claim 1 , wherein the excipient comprises one or more of water, physiological saline, artificial cerebrospinal fluid, and albumin.

9. The pharmaceutical composition of claim 1 , wherein the composition is formulated for oral or parenteral administration.

10. The pharmaceutical composition of claim 1 , wherein the dosage form of the composition is an infusion, a suppository, a transnasal agent, a sublingual agent, or a percutaneous absorbent.

Assignees

• Daiichi Sankyo Co Ltd

Inventors

• Hiruma Yoshiharu
• Tsuda Eisuke
• Takizawa Takeshi
• Nakayama Makiko

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P3/14

  for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title